Last reviewed · How we verify

NCT04502654

Rehabilitation for Thoracoscopic Lobectomy

Completed Last updated 16 August 2021
What this trial tests

trial testing Actiwatch 2 (Philips Respironics, Murrysville, USA) in Lung Neoplasms in 32 participants. Completed in 21 July 2021.

Timeline
15 September 2020
Primary endpoint
21 July 2021
21 July 2021

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusCompleted
Study typeOBSERVATIONAL
Enrollment32
Start date15 September 2020
Primary completion21 July 2021
Estimated completion21 July 2021
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Lung Neoplasms or Rehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this research is to compare the functional recovery after discharge with the preoperative physical activity as a hypothesis generating study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lung Neoplasms

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04502654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing